Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials

Background Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has been shown to induce beneficial changes in the lipid profile and reduce the risk of...

Full description

Saved in:

Bibliographic Details
Published in:	Lipids in health and disease Vol. 22; no. 1; pp. 1 - 12
Main Authors:	Wretlind, Asger, Curovic, Viktor Rotbain, de Zawadzki, Andressa, Suvitaival, Tommi, Xu, Jin, Zobel, Emilie Hein, von Scholten, Bernt Johan, Ripa, Rasmus Sejersten, Kjaer, Andreas, Hansen, Tine Willum, Vilsbøll, Tina, Vestergaard, Henrik, Rossing, Peter, Legido-Quigley, Cristina
Format:	Journal Article
Language:	English
Published:	London BioMed Central 26.09.2023 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Analysis Antidiabetics Biomedical and Life Sciences Calibration Cardiovascular disease Cardiovascular diseases Care and treatment Ceramide Ceramides Cholesterol, LDL Clinical Nutrition Clinical trials Development and progression Diabetes Diabetes mellitus (non-insulin dependent) Dosage and administration Drug therapy Gastrointestinal surgery GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Health aspects Insulin resistance Life Sciences Lipidology Lipids Liquid chromatography Liraglutide Mass spectrometry Mass spectroscopy Measurement Medical Biochemistry Placebos Plasma Precision medicine Scientific imaging Statistical analysis Type 2 diabetes Denmark Type 2 diabetes Ceramide Cardiovascular disease Liraglutide
ISSN:	1476-511X, 1476-511X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!